In common cancers such as NSCLC, publications have reported on an overall concordance of 81% when focused on one specific gene alteration such as EGFR, whereas the concordance rate was 53% when the concordance analysis included all alterations that were potentially detectable by both tests (i.e., included in both gene panels) as in our study (1, 17). This evidence concerns the gene EGFR and non-small cell lung carcinoma.